GlaxoSmithKline plc (LON:GSK) had its price objective upped by investment analysts at J P Morgan Chase & Co from GBX 1,670 ($21.13) to GBX 1,750 ($22.14) in a note issued to investors on Friday, May 12th. The firm currently has a “neutral” rating on the stock. J P Morgan Chase & Co’s price target would indicate a potential upside of 3.86% from the company’s current price.
GSK has been the topic of a number of other research reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a GBX 1,700 ($21.51) price objective on shares of GlaxoSmithKline plc in a research note on Monday, February 6th. Liberum Capital reiterated a “buy” rating and issued a GBX 1,900 ($24.04) target price on shares of GlaxoSmithKline plc in a report on Thursday, March 9th. Goldman Sachs Group, Inc. (The) lifted their target price on GlaxoSmithKline plc from GBX 1,800 ($22.77) to GBX 1,850 ($23.40) and gave the stock a “buy” rating in a report on Tuesday, January 24th. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a report on Thursday, January 26th. Finally, Credit Suisse Group reiterated a “neutral” rating and issued a GBX 1,750 ($22.14) target price on shares of GlaxoSmithKline plc in a report on Thursday, February 9th. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of GBX 1,745.17 ($22.08).
Shares of GlaxoSmithKline plc (GSK) traded up 0.06% during mid-day trading on Friday, reaching GBX 1685.00. The company’s stock had a trading volume of 19,969,256 shares. The company’s 50-day moving average price is GBX 1,647.07 and its 200-day moving average price is GBX 1,604.10. The stock’s market capitalization is GBX 82.33 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,363.00 and a 12-month high of GBX 1,745.56.
The company also recently announced a dividend, which will be paid on Thursday, July 13th. Shareholders of record on Thursday, May 11th will be given a dividend of GBX 19 ($0.24) per share. This represents a yield of 1.21%. The ex-dividend date of this dividend is Thursday, May 11th.
In related news, insider Dominic Redfern purchased 230 shares of GlaxoSmithKline plc stock in a transaction dated Thursday, April 13th. The stock was purchased at an average cost of GBX 1,639 ($20.73) per share, with a total value of £3,769.70 ($4,768.75). Also, insider Vivienne Cox purchased 335 shares of GlaxoSmithKline plc stock in a transaction dated Wednesday, April 26th. The stock was bought at an average cost of GBX 1,583 ($20.03) per share, with a total value of £5,303.05 ($6,708.48). Over the last ninety days, insiders have acquired 662 shares of company stock valued at $1,067,188.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.